{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:34:49Z","timestamp":1791945289489,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13256-018-1619-x","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T04:50:22Z","timestamp":1522817422000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature"],"prefix":"10.1186","volume":"12","author":[{"given":"Yusuke","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Hirahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunsuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Taniura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Hyakudomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"key":"1619_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.lpm.2008.10.020","volume":"38","author":"J Mychaluk","year":"2009","unstructured":"Mychaluk J, Piprot C, Sevestre H, Merviel P, Gondry J, Fauvet R. Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer. Presse Med. 2009;38:1370\u20134.","journal-title":"Presse Med"},{"key":"1619_CR2","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s10637-010-9505-4","volume":"29","author":"E Lecarpentier","year":"2011","unstructured":"Lecarpentier E, Ouaffi L, Mir O, Berveiller P, Maurel M, Pujade-Lauraine E, Bouillot JL, Veyrie N. Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases. Investig New Drugs. 2011;29:1500\u20133.","journal-title":"Investig New Drugs"},{"key":"1619_CR3","first-page":"3239","volume":"28","author":"R Gray","year":"2009","unstructured":"Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;28:3239\u201347.","journal-title":"J Clin Oncol"},{"key":"1619_CR4","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of Human epidermal Growth Factor Receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252\u201369.","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"1619_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/jco.2010.28.15_suppl.1021","volume":"28","author":"A Brufsky","year":"2010","unstructured":"Brufsky A, Rivera RR, Hurvitz SA, Bondarenko IN, Smirnov V, Valero V, et al. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER-2 negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2010;28(Suppl 15):1021.","journal-title":"J Clin Oncol"},{"key":"1619_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139.","journal-title":"Nat Med"},{"key":"1619_CR7","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"67","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanism of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;67:1788\u201395.","journal-title":"Br J Cancer"},{"key":"1619_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"23","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;23:2335\u201342.","journal-title":"N Engl J Med"},{"key":"1619_CR9","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"12","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, O\u2019Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;12:1539\u201344.","journal-title":"J Clin Oncol"},{"key":"1619_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60\u20135.","journal-title":"J Clin Oncol"},{"key":"1619_CR11","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","volume":"16","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;16:3706\u201312.","journal-title":"J Clin Oncol"},{"key":"1619_CR12","doi-asserted-by":"crossref","first-page":"154s","DOI":"10.1200\/jco.2006.24.18_suppl.3535","volume":"24","author":"M Sugrue","year":"2006","unstructured":"Sugrue M, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol. 2006;24:154s.","journal-title":"J Clin Oncol"},{"key":"1619_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","volume":"10","author":"S Hapani","year":"2009","unstructured":"Hapani S, Chu D, Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol. 2009;10:559\u201368.","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"1619_CR14","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1200\/jco.2008.26.15_suppl.4105","volume":"26","author":"M Sugrue","year":"2008","unstructured":"Sugrue M, Purdie D, Feng S, Flynn P, Grothey A, Sargent D, et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Result from the BriTE observational cohort study (OCS). J Clin Oncol. 2008;26(suppl 15):4105.","journal-title":"J Clin Oncol"},{"key":"1619_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.5833\/jjgs.42.1528","volume":"42","author":"K Takaya","year":"2009","unstructured":"Takaya K, Yoshiro K, Tomohiro N, Hiroyuki T, Kouzi O, Isao N, et al. A Case of a Bevacizumab-Associated Penetration into the Mesocolon, undergoing Right Colectomy with Primary Anastomosis. Jpn J Gastroenterol. 2009;42:1528\u201333.","journal-title":"Jpn J Gastroenterol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13256-018-1619-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-018-1619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:36:26Z","timestamp":1604104586000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-018-1619-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1186\/s13256-018-1619-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"10 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study has been approved by the research ethics committee of Shimane University, Faculty of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s next-of-kin for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"84"}}